These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 28273032)

  • 1. The efficacy of modified docetaxel-cisplatin-5-fluorouracil regimen as first-line treatment in patients with alpha-fetoprotein producing gastric carcinoma.
    Bozkaya Y; Doğan M; Yazıcı O; Erdem GU; Demirci NS; Zengin N
    Bosn J Basic Med Sci; 2017 May; 17(2):138-143. PubMed ID: 28273032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution.
    Inal A; Kaplan MA; Kucukoner M; Isikdogan A
    Neoplasma; 2012; 59(2):233-6. PubMed ID: 22248282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of cisplatin-5-fluorouracil-folinic acid versus modified docetaxel-cisplatin-5-fluorouracil regimens in the first-line treatment of metastatic gastric cancer.
    Kos FT; Uncu D; Ozdemir N; Budakoglu B; Odabaş H; Abali H; Oksuzoglu B; Aksoy S; Zengin N
    Chemotherapy; 2011; 57(3):230-5. PubMed ID: 21597287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
    Shah MA; Janjigian YY; Stoller R; Shibata S; Kemeny M; Krishnamurthi S; Su YB; Ocean A; Capanu M; Mehrotra B; Ritch P; Henderson C; Kelsen DP
    J Clin Oncol; 2015 Nov; 33(33):3874-9. PubMed ID: 26438119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.
    Wang J; Xu R; Li J; Bai Y; Liu T; Jiao S; Dai G; Xu J; Liu Y; Fan N; Shu Y; Ba Y; Ma D; Qin S; Zheng L; Chen W; Shen L
    Gastric Cancer; 2016 Jan; 19(1):234-44. PubMed ID: 25604851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma.
    Ozdemir NY; Abali H; Oksüzoğlu B; Budakoglu B; Uncu D; Güler T; Odabaşi H; Zengin N
    Med Oncol; 2010 Sep; 27(3):680-4. PubMed ID: 19633962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study.
    Demirci NS; Aksoy S; Özdemir NY; Erdem GU; Ozcelik M; Tanrikulu E; Eren T; Bozkaya Y; Sahin S; Başol F; Aslan SA; Zengin N; Güllü İ
    Curr Med Res Opin; 2017 Mar; 33(3):401-407. PubMed ID: 27817239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced signet-ring cell carcinoma of the stomach: Clinicopathological characteristics of patients and efficacy of the modified docetaxel, cisplatin, and fluorouracil regimen.
    Bozkaya Y; Erdem GU; Özdemir NY; Hocazade C; Yazici O; Demirci NS; Zengin N
    J Cancer Res Ther; 2018 Sep; 14(Supplement):S742-S747. PubMed ID: 30249897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial.
    Ochenduszko S; Puskulluoglu M; Konopka K; Fijorek K; Urbanczyk K; Budzynski A; Matlok M; Lazar A; Sinczak-Kuta A; Pedziwiatr M; Krzemieniecki K
    Med Oncol; 2015 Oct; 32(10):242. PubMed ID: 26354521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Docetaxel-cisplatin-5-FU combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric cancer].
    Kang SH; Kim JI; Goh PG; Hwang SW; Kwon DS; Nam KW; Kang HM; Kang YS; Moon HS; Kim SH; Seong JK; Lee BS; Jeong HY
    Korean J Gastroenterol; 2007 Sep; 50(3):157-63; discussion 207-9. PubMed ID: 17885280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of FOLFOX and Modified DCF Chemotherapy Regimen in Patients with Advanced Gastric Adenocarcinoma.
    Pourghasemian M; Danandeh Mehr A; Molaei M; Habibzadeh A
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2337-2341. PubMed ID: 32856863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FLEP chemotherapy for alpha-fetoprotein-producing gastric cancer.
    Kochi M; Fujii M; Kaiga T; Takahashi T; Morishita Y; Kobayashi M; Kasakura Y; Takayama T
    Oncology; 2004; 66(6):445-9. PubMed ID: 15452373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive and prognostic value of serum AFP level and its dynamic changes in advanced gastric cancer patients with elevated serum AFP.
    Wang YK; Shen L; Jiao X; Zhang XT
    World J Gastroenterol; 2018 Jan; 24(2):266-273. PubMed ID: 29375212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study.
    Polyzos A; Felekouras E; Karatzas T; Griniatsos J; Dimitroulis D; Polyzos K; Kontzoglou K; Mantas D; Karavokyros J; Nikiteas N; Tsavaris N; Syrigos K; Vafiadis I
    Anticancer Res; 2012 Sep; 32(9):4151-6. PubMed ID: 22993377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A modified DCF regimen as primary treatment for patients with metastatic gastric cancer.
    Koca D; Dogan E; Yardim H; Duzen O; Karaca S
    J BUON; 2013; 18(2):377-84. PubMed ID: 23818349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer.
    Kucukzeybek Y; Dirican A; Erten C; Somali I; Can A; Demir L; Bayoglu IV; Akyol M; Medeni M; Tarhan MO
    Asian Pac J Cancer Prev; 2012; 13(6):2771-4. PubMed ID: 22938457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose docetaxel/cisplatin - leucovorin and 46 hour infusional fluorouracil in metastatic gastric carcinoma.
    Alici S; Buyukberber S; Alkis N; Benekli M; Ozkan M; Bilici A; Demirci U; Karaca H; Arpaci E; Gumus M; Altunbas M; Dane F; Turk HM;
    Asian Pac J Cancer Prev; 2013; 14(1):423-7. PubMed ID: 23534766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified administration schedule of docetaxel, cisplatin, and fluorouracil for advanced or recurrent gastric cancer with gastrointestinal stenosis.
    Muto O; Sawada T; Kotanagi K; Sato K; Kichiraku T; Iwasaki W; Kikkawa M; Ouchi S; Kotanagi H
    Gan To Kagaku Ryoho; 2014 Oct; 41(10):1227-30. PubMed ID: 25335704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastric adenocarcinoma with neuroendocrine differentiation: Clinicopathological features and efficacy of modified DCF chemotherapy.
    Bozkaya Y; Ozdemir N; Colak A; Zengin N
    J BUON; 2017; 22(4):919-925. PubMed ID: 29155521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
    Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.